By Hanna Vioque ( January 15, 2026, 4:03 PM GMT) -- Teva has asked a London judge to nix a supplementary protection certificate extending protection for a Novartis hypertension treatment, arguing that the underlying patent has always been invalid as it looks to launch a generic version....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.